Latest Centocor Stories
NEW BRUNSWICK, N.J., Dec. 30, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 33(rd) Annual JP Morgan Health Care Conference on Monday, Jan.
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.
Save the Children named as Enterprise Wide Global Partner NEW BRUNSWICK, N.J., Nov.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
QUEENSLAND, Australia, Oct.
Acquisition Strengthens Existing Pipeline in Viral Diseases NEW BRUNSWICK, N.J., Sept.
NEW BRUNSWICK, N.J., Sept. 3, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Morgan Stanley Health Care Conference on Wednesday, Sept.
BioScience Laboratories, Inc.
- An imitative word; an onomatopoetic word.